

1 **Complementary effect of *Zingiber officinalis* extract and citral in counteracting non allergic**
2 **nasal congestion by simultaneous loading in ad hoc formulated phospholipid vesicles**

3
4

5 Eleonora Casula^a, Maria Manconi^{a,*}, Tania Belen Lopez-Mendez^{b,c}, Jose Luis Pedraz^{b,c,d}, Esteban
6 Calvo^e, Antonio Lozano^e, Marco Zaru^f, Ines Castangia^a, Germano Orrù^g, Sara Fais^g, Maria Letizia
7 Manca^a

8

9 ^a Dept. of Scienze della Vita e dell'Ambiente, University of Cagliari, via Ospedale 72, 09124 Cagliari,

10 Italy

11 ^b NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque

12 Country (UPV/EHU), Paseo de la Universidad 7, 01006 Vitoria-

13 Gasteiz, Spain

14 ^c Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine

15 (CIBER-BBN), 01006 Vitoria-Gasteiz, Spain

16 ^d Bioaraba, NanoBioCel Research Group, 01006 Vitoria-Gasteiz, Spain

17 ^e LIFTEC, CSIC – Universidad de Zaragoza, María de Luna, 10, 50018 Zaragoza, Spain

18 ^f Icnoderm Srl, Sardegna Ricerche Ed. 5, Pula, 09010 Cagliari, Italy

19 ^g Molecular Biology Service Lab, Department of Surgical Science, University of Cagliari, Via

20 Ospedale 54, 09124 Cagliari, Italy

21 * Corresponding author:

22 E-mail address: manconi@unica.it (M. Manconi).

23

24 **Abstract**

25 Natural nasal spray formulations were prepared by using *Zingiber officinalis* (*Z. officinalis*) extract

26 and citral synergically loaded into specifically designed phospholipid vesicles. Phospholipid vesicles

27 were selected according to their stabilizing effect on the nasal mucosal barrier, and their effectiveness

28 was further potentiated by the co-loading of *Z. officinalis* extract as antioxidant and anti-

29 inflammatory agent, and citral as antibacterial molecule.

30 Cryo-TEM images confirmed the formation of morphologically homogeneous and small vesicles,
31 sized around 100 nm, negatively charged (-44 mV) and highly biocompatible (viability $\geq 100\%$) as
32 detected by using epithelial cells. The analysis of size distribution of sprayed droplets, average
33 velocity module and spray cone angle suggested a good aptitude of the vesicles to be nebulized and
34 their effective deposition in the nasal cavity. Moreover, vesicles were effectively capable of inhibiting
35 some nasal pathogenic bacteria (i.e. *Streptococcus pyogenes*, *Staphylococcus aureus*, *Escherichia*
36 *coli*) and to protect the epithelial cells against oxidative damage. The formulations are natural and
37 safe, and all of them have shown promising technological and biological properties suggesting their
38 possible application in the nasal cavity for the treatment of congestions and non-allergic rhinitis.

39

40 **Introduction**

41 In the last years the interest towards natural products has grown continuously especially among the
42 new generation of consumers. The society today is more vigilant about ecological and environmental
43 issues, and the spread of green philosophies and lifestyles has contributed to a greater awareness of
44 consumers' health, which find natural derivatives more attractive than synthetic compounds. Given
45 that, scientific community is focusing on the research of natural products as valid alternative to
46 prevent degenerative or chronic pathologies or treat a wide range of diseases, especially in patients
47 with mild and moderate symptoms [1]. Local treatments with phytochemicals offer many advantages
48 over systemic administration, directly reaching the diseased area with minimal invasiveness,
49 minimizing side effects and facilitating both auto medication and patient adherence to the therapeutic
50 plan. Mucosae have been recognized as attractive application sites for local administration of
51 therapeutics due to their enhanced permeability, high accessibility and reduced barrier function [2].
52 Nasal mucosa is characterized by porous epitheliums, large absorption area, and low enzyme activity,
53 which make it an advantageous administration route for local therapy of nasal diseases [3].
54 Inflammation with or without bacterial infections of nasal mucosa and paranasal sinus are commonly
55 encountered in diagnostic histopathology. They may be limited to the nasal cavity (rhinitis) or to the

56 paranasal sinuses (sinusitis) or, as in most cases, both sites can be involved (rhinosinusitis) [4]. Their
57 large incidence is caused by the primary and constant contact of nasal mucosa with the outside
58 environment and, therefore, with physical, chemical and infectious agents [5]. As defense, nasal
59 mucosa creates a physical barrier by secreting antimicrobial peptides and expelling foreign molecules
60 through mucociliary clearance.

61 According to the new philosophy of safe and natural treatments, several natural-based products have
62 been designed for the local treatment of nasal diseases. They are usually delivered by spray pumps,
63 but to provide an effective local effect they must have adequate spray plume and droplet size
64 distribution. These parameters can positively affect the deposition zone, improving the beneficial
65 effect of the bioactives at local level, by enhancing their accumulation and efficacy in the anterior
66 nose [6]. Nasal sprays containing liposomes are natural alternative mainly composed of
67 phospholipids, which supplement the components of mucosal cells restoring the protective secretion
68 film, whose functions are moistening, defense, and mucociliary clearance. Liposome's effectiveness
69 can be improved by the incorporation of other natural components or extract exerting anti-
70 inflammatory, antioxidant, and antibacterial activities.

71 In this study, aiming at preparing a total natural and green nanotechnological formulation for the local
72 treatment of nasal congestions, liposomes were enriched with sodium deoxycholate thus obtaining
73 transfersomes, and citral (3,7-dimethyl-2,6-octadienal) and *Z. officinalis* extract were simultaneously
74 loaded. Sodium deoxycholate is a bile surfactant, which acts by destabilizing cellular membranes,
75 thus improving the chemical penetration and absorption in the nasal cavity [7]. Citral is a
76 monoterpene aldehyde naturally found in herbs, plants and oils such as lemongrass (*Cymbopogon*
77 *citratum*) with antioxidant, anti-bacterial and anti-fungal efficacy, along with expectorant and
78 spasmolytic properties [8]. However, it is unstable and sensitive to oxygen, temperature and light,
79 and poorly soluble in water, thus its loading into phospholipid vesicles can enhance stability,
80 solubility, bioavailability and antimicrobial efficacy [9,10]. *Z. officinalis* contains various
81 phytochemicals such as flavonoids, carbohydrates, proteins, alkaloids, glycosides, saponins, steroids,

82 terpenoids, tannin and phenolic compounds [11]. Phenolic compounds, responsible of its peculiar
83 taste and odor, also exert a pharmacological activity. Among all, gingerol is the most abundant
84 phenolic compound and provides anti-bacterial, anti-oxidant, antifungal, antiviral and anti-
85 inflammatory activities [12]. *Z. officinalis* extract is generally contained in products for topical
86 application, chewable tablets and inhalable dispersions [13]. According to Stappen et al. the
87 inhalation is the most effective administration method for the treatment of infectious diseases of the
88 upper respiratory tract and respiratory diseases, such as cough, cold and asthma, acting as
89 antibacterial and anti-inflammatory [13,14].

90 The main physicochemical properties (i.e., mean size, electrical charge, and entrapment efficiency)
91 and the feasibility to be sprayed in the nose apparatus (i.e., droplet size distribution, average drop
92 velocity and initial spray plume angle) of prepared vesicles were measured. The cytotoxicity of the
93 formulations, the ability to protect epithelial cells against oxidative stress along with the antibacterial
94 efficacy against *Streptococcus pyogenes*, *Staphylococcus aureus*, *Escherichia coli* were determined
95 in vitro.

96

97 **Materials and methods**

98 **Materials**

99 Soy phosphatidylcholine Phospholipon[®] 90G (P90G) was purchased from AVG S.r.l (Garbagnate
100 Milanese, Italy). Extract of *Z. officinalis Roscoe* containing 5% of gingerol was purchased by
101 Farmalabor Srl (Milan, Italy). Citral, sodium deoxycholate and 2,2-diphenyl-1-picrylhydrazyl
102 (DPPH) were purchased from Sigma-Aldrich (Milan, Italy). Reagents and plastics for cell culture
103 were purchased from Life Technologies Europe (Monza, Italy).

104 **Liposome preparation**

105 Phospholipid P90G (90 mg/ml) was mixed with sodium deoxycholate (10 mg/ml) and hydrated with
106 water. Dispersion was sonicated (15 cycles, 5 on /2 off, amplitude 13) using a Soniprep 150 sonicator
107 (MSE Crowley, London, UK). After sonication citral (180 mg/ml) and *Z. officinalis* extract (10

108 mg/ml) were added and the dispersion was further sonicated (15 cycles, 5 on /2 off, amplitude 13 μ).
109 Empty vesicles without citral and *Z. officinalis* extract were prepared as well and used as reference.

110 **Liposome characterization**

111 Observation of vesicles by cryogenic transmission electron microscopy (cryo-TEM) was performed
112 using a TECNAI G2 20 TWIN (FEI), working at 200 KeV voltage in a bright-field and low-dose
113 image mode as previously reported [15].

114 Average diameter, polydispersity index and zeta potential of vesicles were determined by using a
115 Zetasizer Ultra (Malvern Instruments, Worcestershire, UK) [16]. These parameters were monitored
116 for 1 months at 4 °C to evaluate the long-term stability of vesicles. Before the analyses samples were
117 diluted (1:100) with water to be optically clear and avoid the attenuation of the laser beam by the
118 particles and measured at 25 °C (Oleuropein Mo Nanomedicine).

119 The non-incorporated bioactives was eliminated by dialysis method against water for 2 h and
120 replacing the water after one hour, as previously reported [15]. The antioxidant activity of samples,
121 before and after the dialysis process, was measured by means of DPPH colorimetric test. 20 μ l of
122 each formulation was dissolved in 1980 μ l of DPPH methanolic solution (40 μ g/ml) and the obtained
123 solutions were incubated in the dark for 30 min at room temperature. Then, the absorbance was
124 measured at $\lambda = 517$ nm by means of a UV spectrophotometer (Lambda 25, Perkin Elmer, Milan,
125 Italy). All experiments were performed in triplicate. The antioxidant activity (%) was calculated
126 according to Casula et al. [15].

127 The entrapment efficiency of the vesicles was expressed as the percentage of the antioxidant activity
128 after dialysis versus the value found before dialysis [10].

129 **Droplet size distribution**

130 Droplet size distribution was evaluated using a Malvern Spraytec® laser diffractometer (Malvern
131 Panalytical Ltd., Malvern, U.K.). Formulation (6 ml) was loaded in commercial devices (20 ml)
132 kindly supplied by FAES laboratories. According to Food and Drug Administration (FDA) [17],
133 experiments were performed at room temperature in triplicate at 4 and 7 cm of distance from the

134 nozzle exit [15]. The device was turned at a 45° angle respect to the laser beam. The focal length of
135 the lens was 300 mm; the dispersant refractive index was $1.00 + 0.000i$ and the particulate refractive
136 index was $1.33 + 0.000i$ (water droplets in air). Data were reported as volume diameter expressed as
137 10%, 50% and 90% of the ejected volume. Span was also reported as correlation value among D10,
138 D50 and D90, as $(D90-D10)/D50$.

139 **Spray structure, drop average velocity module and spray angle**

140 The average velocities of the drops and the initial spray opening angle of vesicles were determined
141 by means of Particle Image Velocimetry and by laser plane visualization [15]. Instantaneous images
142 of the atomization process were obtained with a Hamamatsu (1024×1344 pixels 12-bit C4742-95-
143 12 ORCA-ER) charge-coupled device camera (Hamamatsu Photonics, Shizuoka, Japan) equipped
144 with a Nikon 50 mm F#1.2 lens. To freeze the motion, a Quanta System model PILS Nd: YAG laser
145 (Quanta System, S.p.A., Milan, Italy), was used illuminating a vertical plane across the center of the
146 spray. PIV image pairs were acquired with a time interval of 30 μ s and processed with the CCDPIV
147 computer code (Laboratory for Turbulence Research in Aerospace and Combustion (LTRAC) in
148 Monash University, Melbourne, Australia).

149 The spray cone angle was determined tracing the limits of the spray in an image obtained averaging
150 100 instantaneous frames [15]. To actuate the atomizers avoiding human errors, a pneumatic device
151 was used, with an atomization pulse duration set to 150 ms. The instantaneous images were acquired
152 83 ms after the start of the atomization.

153 **Biocompatibility of extract loaded vesicles in keratinocytes**

154 Human epithelial cells (HaCaT) were grown as monolayers in 75 cm² flasks, incubated with 100%
155 humidity and 5% CO₂ at 37°C. Cells were cultured with Dulbecco's Modified Eagle Medium
156 (DMEM) with high glucose, supplemented with 10% of fetal bovine serum and
157 penicillin/streptomycin. The cells were seeded into 96-well plates at a density of 7.5×10^3 cells/well
158 and after 24 h of incubation, were exposed for 48 h to the formulation properly diluted to reach
159 different concentrations of citral (18, 1.8, 0.18 μ g/ml) and *Z. officinalis* (1, 0.1, 0.01 μ g/ml). As

160 comparison, citral and *Z. officinalis* dispersed in water at the same dilutions were tested. The possible
161 toxic effect of the formulations towards HaCaT cells was assessed by measuring cell viability by
162 means of the MTT (tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
163 test as previously reported [18]. All the experiments were repeated at least three times and each time
164 in triplicate. The results are expressed as the percentage of viable cells compared to untreated cells
165 (100% viability).

166 **Protective ability of extract loaded vesicles against oxidative damage induced in cells**

167 HaCaT cells (5×10^4 cells/well) were seeded in 96-well plates with 200 μ l of culture medium and
168 incubated at 37°C for 24 h, then stressed for 4 h with hydrogen peroxide (1:50,000) and
169 simultaneously treated with the vesicular formulations (citral 18, 1.8, 0.18 μ g/ml and *Z. officinalis* 1,
170 0.1, 0.01 μ g/ml). Unstressed cells were used as positive control (100% viability); cells stressed with
171 hydrogen peroxide and untreated were used as negative control. After 4 h of incubation the medium
172 was removed and the viability of the cells was determined by the MTT colorimetric test, as reported
173 above.

174 **Antibacterial Assay**

175 The antibacterial activity of vesicles was measured by Kirby Bauer agar diffusion method. The
176 experimental procedures were performed by using three different Gram-positive and Gram-negative
177 bacterial species, already described in nasal infections [19]: *Staphylococcus aureus* ATCC 6538
178 (American Type Culture Collection), *Streptococcus pyogenes* clinical isolate NC4, *Escherichia coli*
179 ATCC 7075. The antimicrobial susceptibility testing was done by a modified procedure derived from
180 the CLSI guidelines (<https://clsi.org/>) [20]. Briefly, a suspension containing $1 \cdot 10^7$ bacterial cells/ml
181 was inoculated onto the surface of a 90 \emptyset Petri plate containing an agarized growth media: (i) Muller-
182 Hinton agar was used for *S. aureus* and *E. coli*, while Schaedler agar for *S. pyogenes* (Microbiol Uta,
183 Cagliari). 100 μ l of each undiluted formulation was put inside a well performed on the growth
184 medium's surface. The antimicrobial activity was expressed as mm of inhibition diameter around the

185 well after the microbial growth at 37 °C in 5% CO₂ for *S. pyogenes* and at 37 °C in the air for other
186 strains. All experiments were performed in triplicate.


187 **Statistical analysis**

188 Statistical analysis was performed by processing the collected data by ANOVA, T-Test and F-Test.
189 Results were expressed as mean value ± standard deviation. The minimum level of significance
190 chosen was $p < 0.05$.

191

192 **Results**

193 Aiming at obtaining phospholipid vesicles with a powerful antioxidant, antiinflammatory and
194 antibacterial effect, several vesicular formulations were prepared by using different preparation
195 methods, phospholipids, surfactants, and water co-solvents and loading increasing amount of both
196 citral and *Z. officinalis* extract. After several attempts, citral (180 mg/ml) and *Z. officinalis* extract
197 (10 mg/ml) were simultaneously loaded adding sodium deoxycholate (10 mg/ml) to phospholipid
198 and obtaining transfersomes.



199

200 **Fig. 1.** Representative cryo-TEM images of transfersomes loading citral and *Z. officinalis* extract

201

202

203 **Vesicle characterization**

204 Cryo-TEM images disclosed the formation of multilamellar and spherical transfersomes (Fig. 1). The
205 mean diameter and zeta potential of transfersomes loading citral and *Z. officinalis* extract were
206 measured along with that of empty vesicles, used as comparison (Table 1). Transfersomes loading
207 citral and *Z. officinalis* extract were slightly larger than the empty vesicles, indicating a contribution
208 of both bioactives in the bilayer assembling. The zeta potential was highly negative and the low
209 polydispersity index (0.21) indicated a monodispersed sample.

210

211 **Table I.** Mean diameter (MD), polydispersity index (PI), zeta potential (ZP) of empty and bioactive
212 loaded vesicles, and entrapment efficiency (EE) of the empty and extract loaded vesicles. Data
213 represent the means \pm SD of at least six replicates. Each symbol (*, +, #, °) indicates a value
214 statistically different from the others ($p > 0.05$).

	MD (nm)	PI	ZP (mV)	EE (%)
Empty PEVs	*90 \pm 2	0.2	°-54 \pm 5	
Citral EO+<i>Z. officinalis</i> liposomes	+110 \pm 1	0.21	#-44 \pm 3	74 \pm 10

215

216 **Droplet size distribution**

217 Vesicle formulation were designed for nasal administration and the key parameters to reach the
218 anterior cavity of nose (droplet size distribution, velocity and plume angle) were evaluated. The
219 aptitude of citral and *Z. officinalis* extract in aqueous dispersion with sodium deoxycholate to be
220 sprayed was measured as well, mainly aiming at evaluating the improvement due to vesicle loading.
221 Sprayed particles size must be comprised between 30 and 70 μm for D50, and lower than 200 μm for
222 D90 as recommended by the FDA. The size of droplets generated by transfersomes were very similar
223 to those recommended, only slightly higher, confirming their suitability to reach the anterior cavities
224 of nose (Table II)

225

226 **Tab II.** Distribution of droplet size generated by citral and *Z. officinalis* extract in dispersion or
 227 loaded in transfersomes, at 4 and 7 cm from laser beam. Mean values of three measurements \pm
 228 standard deviations were reported. The same symbol ($\$, \wedge, @, *, \circ, \#$) indicates the same value.


		D10 (μm)	D50 (μm)	D90 (μm)	SPAN (μm)
4 cm	Dispersion	@22 \pm 0.5	\circ 46 \pm 1	#101 \pm 11	2 \pm 0.2
	Transfersomes	$\$$ 27 \pm 0.5	*49 \pm 1.5	#94 \pm 3	1 \pm 0.05
7 cm	Dispersion	\wedge 28 \pm 2	\circ 46 \pm 2	$\$$ 78 \pm 6	1 \pm 0.1
	Transfersomes	\wedge 30 \pm 0.5	*50 \pm 1.5	#101 \pm 13	1 \pm 0.2

229

230 Measurements of spray plume morphology and angle

231 When sprayed, the aqueous dispersion of citral and extract produced a large plume with low droplet
 232 consistency, where the droplets were not uniformly distributed but split in the external areas. On the
 233 contrary, transfersomes generated a plume with a spatial structure initially corresponding to a hollow
 234 cone spray whose core is filled with drops (perhaps from the smallest fractions) downstream. Their
 235 plume was larger, and the outlet jet appears split into two more consistent parts, upper and lower,
 236 generating almost a hollow cone (Fig. 2).

237



238

239 **Figure 2.** Representative images of instant visualization of sprays generated transfersomes (A) and
 240 water dispersion (B).


241

242 **Measurements of average velocity module**

243 The analysis of average velocity modules was performed by using citral and extract dispersed in water
244 or loaded in vesicles (Fig. 3). The bioactive dispersion formed a plume shaped like a scissor with
245 separate flows where the velocity developed. Instead, in the middle of the cone, a light and dark blue
246 zone was presented indicating that the velocity of sprayed droplets decreased sharply (Fig. 3-A). On
247 the contrary, the spray plume generated by transfersomes appeared more homogeneous in shape and
248 velocity trend, that decrease in a coherent way from the nozzle (Fig. 3-B).

249 The high-speed and the angle obtained during the spray were measured (Table 3). The speed of
250 transfersomes droplets was slightly lower (~ 13 m/s) than that of dispersion droplets (~ 15 m/s) angle
251 of the spray generated by transfersomes was almost the half ($\sim 27^\circ$) than that of the dispersion ($\sim 48^\circ$).

252



253

254 **Figure 3.** Images of distribution of average velocity of drops generated by transfersomes (A) and
255 water dispersion (B).

256

257

258

259

260 **Table III.** High-speed values and spray angle measured from the plume generated by water
261 dispersion and transfersomes.

	High-speed (m/s)	Spray angle (°)
Dispersion	15	48
Transfersomes	13	27

262

263 **Antibacterial Assay**

264 The combination of citral and *Z. officinalis* extract disclosed to be synergically efficient in
265 counteracting the growth of *S. pyogenes*, *S. aureus* and *E. coli* (Table 4). Indeed, when combined in
266 dispersion or in vesicles, they inhibited the proliferation of the three strains and the inhibition zone
267 was ~ 30 mm, irrespective to the tested strain. The effectiveness of citral and *Z. officinalis* extract
268 was the same in dispersion or in transfersomes, except against *E. coli* as the loading in transfersomes
269 slightly improved the inhibition zone from ~27 to ~32 mm, probably thank to the structural
270 architecture of the microorganism, which is Gram-negative, while *S. pyogenes*, *S. aureus* are Gram-
271 positive. The hydrophobic lipopolysaccharide outer membrane of *E. coli* can interact with the
272 liposomes prepared with phosphatidylcholine.

273 The effectiveness of citral dispersion or *Z. officinalis* extract in dispersion was evaluated as well to
274 evaluate their contribution in counteracting the bacterial growth. Citral dispersion was less effective
275 against *S. pyogenes* (15 ± 1 mm) and *E. coli* (11 ± 1 mm) than the dispersion containing both
276 bioactives and was ineffective against *S. aureus*, indicating the contribution of *Z. officinalis* extract.
277 The dispersion of extract alone did not disclose any activity (Table 4).

278 Results confirmed the synergic antibacterial performances of both citral and *Z. officinalis* extract.

279


280

281

282 **Tab IV.** Inhibition zone of *S. pyogenes*, *S. aureus* and *E. coli* provided by citral and *Z. officinalis*
 283 extract loaded in transfersomes or dispersed in water alone or in association. Mean values of three
 284 measurements \pm standard deviations were reported.

	S. pyogenes (mm)	S. aureus (mm)	E. coli (mm)
Citral and extract dispersion	32 \pm 1	31 \pm 1	32 \pm 1
Citral dispersion	32 \pm 1	30 \pm 5	27 \pm 6
Extract dispersion	15 \pm 1	-	11 \pm 1
Citral and extract transfersomes	-	-	-

285



286

287 **Fig. 4.** A) Viability of keratinocytes treated with citral and *Z. officinalis* extract in water dispersion
 288 or loaded in transfersomes at different concentrations (citral 18,1.8, 0.18 $\mu\text{g/ml}$ and *Z. officinalis* 1,
 289 0.1, 0.01 $\mu\text{g/ml}$). Data represent the means \pm standard deviations of at least three experimental
 290 determinations. Each symbol ($\$, \#$) indicates the same value. B) Viability of cells stressed with
 291 hydrogen peroxide and treated with citral and *Z. officinalis* extract in dispersion or loaded in vesicles.
 292 Data are reported as mean values \pm standard deviations of cell viability. Each symbol ($*, \#, \$$)
 293 indicates the same value.

294

295 Discussion

296 Previous studies disclosed that liposomes dispersions locally sprayed on nasal cavity are a valuable
 297 alternative to corticoids or antihistaminic drugs with an appreciable potential to reduce and care
 298 allergic and notallergic rhinitis. In addition, the loading of an antioxidant extract can improve the
 299 protective and regenerative effect of phospholipid vesicles [15]. Given that, in this work the
 300 effectiveness of phospholipid vesicles against rhinitis was improved by loading a natural antibacterial

301 molecule (citral) and an effective antioxidant phytocomplex (*Z. officinalis* extract). The pre-
302 formulation study performed testing different phospholipids, polymers, surfactants and cosolvents,
303 allowed to select transfersomes, containing sodium deoxycholate as edge activator and loading 180
304 mg/ml of citral and 10 mg/ml of extract, as best formulation. Sodium deoxycholate was used thanks
305 to its ability to destabilize phospholipid membranes enhancing the delivery performances of vesicles,
306 especially in skin and mucosa [7]. Citral is an acyclic monoterpene with antibacterial activity,
307 particularly against *Staphylococcus* genera and it is considered a promising candidate for the
308 treatment of *S. aureus* infections resistant to other drugs [21]. To reinforce the antibacterial activity
309 of citral and simultaneously provide a protection against oxidative damages, *Z. officinalis* extract was
310 co-loaded in transfersomes. Indeed, this phytocomplex has been proposed as alternative system in
311 drug resistant microbial diseases and to prevent the damages caused by reactive oxygen species [22].
312 The obtained transferosomes were small, monodispersed and negatively charged with features
313 suitable for their deposition in the nasal mucosa of the anterior cavity of nose. Transfersome
314 dispersion was sprayed in small droplets having a mean diameter $\sim 50\ \mu\text{m}$, which may effectively
315 deposit in the anterior part of the nose according to the FDA recommendations [15]. The plume angle
316 of the bioactives in aqueous dispersion was almost double respect to that of transfersome dispersion.
317 Moreover, the plume of the dispersion shaped like a scissor with separate flows in the peripheral areas
318 and low droplets in the middle, while that generated by the transfersomes appeared narrower with
319 high droplet concentration in the middle. This behavior is predictive of a prevalent deposition in the
320 anterior region of the nose because the breadth of the plume is a key parameter affecting the area of
321 deposition [23]. Thus, overall technological results confirmed that citral and *Z. officinalis* extract
322 loaded transfersomes had suitable properties for the local delivery in the nose as after spraying a
323 narrow (cone angle $\sim 27^\circ$) and full cone of homogeneous droplets sized $\sim 50\ \mu\text{m}$, having high-speed
324 ($\sim 13\ \text{m/s}$) was formed. When deposited in the target site, the transferosomes may favor the
325 accumulation of payloads inside the mucosa where they can exert the antioxidant, anti-inflammatory
326 and antibacterial activities. The selected formulation has a protective effect on keratinocytes and

327 avoid their death caused by the formation of free radicals generated by hydrogen peroxide. The effect
328 was due to the antioxidant components of the *Z. officinalis* extract such as gingerol, pyrogallol p-
329 hydroxybenzoic acid, ferulic acid and p-coumaric acid [24]. Citral is not a strong antioxidant but can
330 synergically potentiate the antioxidant activity of other molecules.

331 The co-loading of citral and *Z. officinalis* extract led to reach a synergic activity, which potentiated
332 the antimicrobial efficacy of formulation against three bacterial strains, *S. pyogenes*, *S. aureus*, *E.*
333 *coli*, which typically colonize the first airways [20,25,26]. Indeed, *Z. officinalis* extract alone did not
334 have any antimicrobial activity but when combined with citral increased the efficacy of this terpene
335 also against *S. aureus*, as previously reported for the combination of citral and quercetin [27].

336 Finally, the antimicrobial and antioxidant effect of both payloads is associated to that of phospholipid
337 vesicles, which are able to supplement phospholipid to the mucosal cells restoring the protective
338 secretion film [28].

339

340 **Conclusion**

341 The overall results based on technological and physicochemical properties of citral and *Z. officinalis*
342 extract loaded into transfersomes suggest that they are suitable to be used as nasal spray because they
343 with the liposomes prepared with phosphatidylcholine.

344 The effectiveness of citral dispersion or *Z. officinalis* extract in dispersion was evaluated as well to
345 evaluate their contribution in counteracting the bacterial growth. Citral dispersion was less effective
346 against *S. pyogenes* (15 ± 1 mm) and *E. coli* (11 ± 1 mm) than the dispersion containing both
347 bioactives and was ineffective against *S. aureus*, indicating the contribution of *Z. officinalis* extract.

348 The dispersion of extract alone did not disclose any activity (Table 4).

349 Results confirmed the synergic antibacterial performances of both citral and *Z. officinalis* extract.

350

351 **CRedit authorship contribution statement**

352 Eleonora Casula: Investigation, Formal analysis, Data curation, Writing – original draft. Maria
353 Manconi: Supervision, Project administration, Data curation, Writing – original draft. Tania Belen
354 Lopez-Mendez: Investigation, Writing – review & editing. Jose Luis Pedraz: Supervision,
355 Methodology, Validation, Writing – review & editing. Esteban Calvo: Methodology, Validation,
356 Writing – review & editing. Antonio Lozano: Methodology, Validation, Writing – review & editing.
357 Germano Orrù: Methodology, Investigation, Data curation. Sara Fais: Methodology, Investigation,
358 Data curation. Marco Zaru: Resources, Writing – review & editing. Ines Castangia: Writing – review
359 & editing. Maria Letizia Manca: Supervision, Methodology, Validation, Writing – review & editing.

360

361 **Declaration of Competing Interest**

362 The authors declare that they have no known competing financial interests or personal relationships
363 that could have appeared to influence the work reported in this paper.

364

365 **Acknowledgements**

366 The authors thank PON-RI 2014–2020 Research and Innovation Program, grant number
367 DOT1304004, for the support. The authors thank for technical and human support provided by TEM
368 measurements carried out in the SGIker Polymer Characterization (UPV/EHU/ ERDF, EU); the
369 NanoBioCel Group of the University of the Basque Country (UPV/EHU), in Vitoria-Gasteiz (Spain);
370 the Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine
371 (CIBER-BBN) of Zaragoza (Spain); the Molecular Biology Service Lab of the University of Cagliari.

372

373

374

375 **References**

376 [1] A. Chandrasekara, F. Shahidi, Herbal beverages: bioactive compounds and their role in disease
377 risk reduction – a review, *J. Tradit. Complement. Med.* 8 (2018) 451–458,
378 <https://doi.org/10.1016/j.jtcme.2017.08.006>.

- 379 [2] C. Bartos, P. Varga, P. Szabó-Révész, R. Ambrus, Physico-chemical and in vitro
380 characterization of chitosan-based microspheres intended for nasal administration,
381 *Pharmaceutics* 13 (2021) 1–13, <https://doi.org/10.3390/pharmaceutics13050608>.
- 382 [3] M. Gao, X. Shen, S. Mao, Factors influencing drug deposition in the nasal cavity upon delivery
383 via nasal sprays, *J. Pharm. Invest.* 50 (2020) 251–259, [https://doi.org/10.1007/s40005-020-](https://doi.org/10.1007/s40005-020-00482-z)
384 00482-z.
- 385 [4] L. Barnes, Diseases of the nasal cavity, paranasal sinuses, and nasopharynx, in: *Surgical*
386 *Pathology of the Head and Neck*, CRC Press, 2020, pp. 352–431,
387 <https://doi.org/10.1201/9781439814093-11>.
- 388 [5] K. Martens, S.F. Seys, Y.A. Alpizar, R. Schrijvers, D.M.A. Bullens, C. Breynaert, S. Lebeer, B.
389 Steelant, Staphylococcus aureus enterotoxin B disrupts nasal epithelial barrier integrity, *Clin.*
390 *Exp. Allergy* 51 (2021) 87–98, <https://doi.org/10.1111/cea.13760>.
- 391 [6] C. Karavasili, D.G. Fatouros, Smart materials: in situ gel-forming systems for nasal delivery,
392 *Drug Discov. Today* 21 (2016) 157–166, <https://doi.org/10.1016/j.drudis.2015.10.016>.
- 393 [7] M. Ghadiri, P.M. Young, D. Traini, Strategies to enhance drug absorption via nasal and
394 pulmonary routes, *Pharmaceutics* 11 (2019), <https://doi.org/10.3390/pharmaceutics11030113>.
- 395 [8] J. Ju, Y. Xie, H. Yu, Y. Guo, Y. Cheng, H. Qian, W. Yao, Analysis of the synergistic antifungal
396 mechanism of eugenol and citral, *LWT* 123 (2020), 109128,
397 <https://doi.org/10.1016/j.lwt.2020.109128>.
- 398 [9] M. Pateiro, F.J. Barba, R. Domínguez, A.S. Sant’Ana, A. Mousavi Khaneghah, M. Gavahian, B.
399 Gómez, J.M. Lorenzo, Essential oils as natural additives to prevent oxidation reactions in meat
400 and meat products: a review, *Food Res. Int.* 113 (2018) 156–166,
401 <https://doi.org/10.1016/j.foodres.2018.07.014>.
- 402 [10] M.L. Manca, M. Manconi, M.C. Meloni, F. Marongiu, M. Allaw, I. Usach, J.E. Peris, E.
403 Escribano-Ferrer, C.I.G. Tuberoso, G. Gutierrez, M. Matos, M. Ghavam, Nanotechnology for
404 natural medicine: formulation of neem oil loaded phospholipid vesicles modified with argan oil

- 405 as a strategy to protect the skin from oxidative stress and promote wound healing, *Antioxidants*
406 10 (2021) 670, <https://doi.org/10.3390/antiox10050670>.
- 407 [11] Q.Q. Mao, X.Y. Xu, S.Y. Cao, R.Y. Gan, H. Corke, T. Beta, H. Bin Li, Bioactive compounds
408 and bioactivities of ginger (*Zingiber officinale roscoe*), *Foods* 8 (2019),
409 <https://doi.org/10.3390/foods8060185>.
- 410 [12] H.Y. Chung, R. Arulkumar, E. Bang, S.-G. Noh, T. Yokozawa, Role of garlic and ginger in anti-
411 oxidative and anti-inflammatory effects in aging, *SDRP J. Food Sci. Technol.* 4 (2019) 788–795,
412 <https://doi.org/10.25177/jfst.4.5.mr.533>.
- 413 [13] I. Stappen, A.S. Hoelzl, O. Randjelovic, J. Wanner, Influence of essential ginger oil on human
414 psychophysiology after inhalation and dermal application, *Nat. Prod. Commun.* 11 (2016) 1569–
415 1578, <https://doi.org/10.1177/1934578x1601101035>.
- 416 [14] G.T. Yocum, J.J. Hwang, M. Mikami, J. Danielsson, A.S. Kuforiji, C.W. Emala, Ginger and its
417 bioactive component 6-shogaol mitigate lung inflammation in a murine asthma model, *Am. J.*
418 *Physiol.. Lung Cell. Mol. Physiol.* 318 (2020) 296, <https://doi.org/10.1152/ajplung.00249.2019>.
- 419 [15] E. Casula, M.L. Manca, M. Perra, J.L. Pedraz, T.B. Lopez-Mendez, A. Lozano, E. Calvo, M.
420 Zaru, M. Manconi, Nasal spray formulations based on combined hyalurosomes and
421 glycerosomes loading zingiber officinalis extract as green and natural strategy for the treatment
422 of rhinitis and rhinosinusitis, *Antioxidants* 10 (2021) 1109,
423 <https://doi.org/10.3390/ANTIOX10071109>.
- 424 [16] V. Melis, M.L. Manca, E. Bullita, E. Tamburini, I. Castangia, M.C. Cardia, D. Valenti, A.M.
425 Fadda, J.E. Peris, M. Manconi, Inhalable polymer-glycerosomes as safe and effective carriers for
426 rifampicin delivery to the lungs, *Colloids Surf. B: Biointerfaces* 143 (2016) 301–308,
427 <https://doi.org/10.1016/j.colsurfb.2016.03.044>.
- 428 [17] USP, FDA, CDER, Guidance for Industry Guidance for Industry Bioavailability and
429 Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action (Draft Guidance).

- 430 <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati>, Distribution.
431 (Accessed 4. June 2013).
- 432 [18] M. Allaw, M. Manconi, M. Aroffu, F. Marongiu, M. Porceddu, G. Bacchetta, I. Usach, R.A.
433 Rached, H.N. Rajha, R.G. Maroun, J.L. Pedraz, T.B. Lopez-Mendez, A. M. Fadda, M.L. Manca,
434 Extraction, characterization and incorporation of hypericum scruglii extract in ad hoc formulated
435 phospholipid vesicles designed for the treatment of skin diseases connected with oxidative stress,
436 *Pharmaceutics* 12 (2020) 1–20, <https://doi.org/10.3390/pharmaceutics12111010>.
- 437 [19] G.M. Nardi, S. Fais, C. Casu, M. Mazur, R. Di Giorgio, R. Grassi, F.R. Grassi, G. Orrù,
438 Mouthwash based on ozonated olive oil in caries prevention: a preliminary in-vitro study, *Int. J.*
439 *Environ. Res. Public Health* 17 (2020) 1–9, <https://doi.org/10.3390/ijerph17239106>.
- 440 [20] G. Orrù, C. Demontis, A. Mameli, E. Tuveri, P. Coni, G. Pichiri, F. Coghe, A. Rosa, P. Rossi,
441 G. D’hallewin, The selective interaction of Pistacia lentiscus Oil vs. Human Streptococci, an old
442 functional food Revisited with new tools, *Front. Microbiol.* 8 (2017) 2067,
443 <https://doi.org/10.3389/fmicb.2017.02067>.
- 444 [21] P. Gupta, D.K. Patel, V.K. Gupta, A. Pal, S. Tandon, M.P. Darokar, Citral, a monoterpenoid
445 aldehyde interacts synergistically with norfloxacin against methicillin resistant *Staphylococcus*
446 *aureus*, *Phytomedicine* 34 (2017) 85–96, <https://doi.org/10.1016/j.phymed.2017.08.016>.
- 447 [22] S. Murugesan, M.R. Venkateswaran, S. Jayabal, S. Periyasamy, Evaluation of the antioxidant
448 and anti-arthritic potential of *Zingiber officinale* Rosc. by in vitro and in silico analysis, *South*
449 *Afric. J. Botany* 130 (2020) 45–53, <https://doi.org/10.1016/j.sajb.2019.12.019>.
- 450 [23] T.E. Natsheh H, Phospholipid vesicles for dermal/transdermal and nasal administration of active
451 molecules: the effect of surfactants and alcohols on the fluidity of their lipid bilayers and
452 penetration enhancement properties, *Molecules* 25 (2020) 2959,
453 <https://doi.org/10.3390/molecules25132959>.

- 454 [24] H. Tohma, I. Gülçin, E. Bursal, A.C. Gören, S.H. Alwasel, E. Köksal, Antioxidant activity
455 and phenolic compounds of ginger (*Zingiber officinale* Rosc.) determined by HPLC-MS/MS, *J.*
456 *Food Meas. Charact.* 11 (2017) 556–566, <https://doi.org/10.1007/s11694-016-9423-z>.
- 457 [25] A. Barberis, M. Deiana, Y. Spissu, E. Azara, A. Fadda, P.A. Serra, G. D'Hallewin, M. Pisano,
458 G. Serreli, G. Orrù, A. Scano, D. Steri, E. Sanjust, Antioxidant, antimicrobial, and other
459 biological properties of pompia juice, *Molecules* 25 (2020) 3186,
460 <https://doi.org/10.3390/molecules25143186>.
- 461 [26] J. Vitonyte, M.L. Manca, C. Caddeo, D. Valenti, J.E. Peris, I. Usach, A. Nacher, M. Matos, G.
462 Gutiérrez, G. Orrù, X. Fernández-Busquets, A.M. Fadda, M. Manconi, Bifunctional viscous
463 nanovesicles co-loaded with resveratrol and gallic acid for skin protection against microbial and
464 oxidative injuries, *Eur. J. Pharm. Biopharm.* 114 (2017) 278–287,
465 <https://doi.org/10.1016/j.ejpb.2017.02.004>.
- 466 [27] S.G. Giteru, R. Coorey, D. Bertolatti, E. Watkin, S. Johnson, Z. Fang, Physicochemical and
467 antimicrobial properties of citral and quercetin incorporated kafirin-based bioactive films, *Food*
468 *Chem.* 168 (2015) 341–347, <https://doi.org/10.1016/j.foodchem.2014.07.077>.
- 469 [28] C. Hahn, M. Böhm, S. Allekotte, R. Mösges, Tolerability and effects on quality of life of
470 liposomal nasal spray treatment compared to nasal ointment containing dexpanthenol or isotonic
471 NaCl spray in patients with rhinitis sicca, *Eur. Arch. Oto-Rhino-Laryngol.* 270 (2013) 2465–
472 2472, <https://doi.org/10.1007/s00405-013-2362-y>.